| Date Filed | Type | Description |
| 04/01/2013 |
8-K
| Bankruptcy or Receivership, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation unde... |
| 03/21/2013 |
8-K
| Quarterly results |
| 03/18/2013 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 03/15/2013 |
8-K
| Material Modifications to Rights of Security Holders, Submission of Matters to a Vote of Security Holders, Financial Statemen... |
| 03/07/2013 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/07/2013 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 03/07/2013 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/05/2013 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| 02/21/2013 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements |
| 02/14/2013 |
SC 13G/A
| FMR LLC reports a 8.4% stake in POLYMEDIX INC |
| 01/23/2013 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits |
| 11/20/2012 |
SC 13D/A
| Target Capital Management reports a 6.9% stake in POLYMEDIX, INC. |
| 11/09/2012 |
10-Q
| Quarterly Report for the period ended September 30, 2012 |
| 11/09/2012 |
8-K
| Quarterly results |
| 09/19/2012 |
GN
| PolyMedix Receives Grant From National Cancer Institute to Study Brilacidin for Oral Mucositis |
| 09/11/2012 |
GN
| PolyMedix Presents New Data on Its Defensin-Mimetic Antibiotics at 52nd Annual ICAAC |
| 09/05/2012 |
GN
| Data Showing Effectiveness of PolyCide Antimicrobial in Surgical Suture Coatings Published in American Chemical Society Journal, Langmuir |
| 08/09/2012 |
10-Q
| Quarterly Report for the period ended June 30, 2012 |
| 08/09/2012 |
8-K
| Quarterly results |
| 08/09/2012 |
GN
| PolyMedix Reports Second Quarter 2012 Financial Results |
| 07/13/2012 |
GN
| PolyMedix Outlines Potential Benefits of GAIN Act to Its Antibiotic Development Program |
| 06/12/2012 |
8-K
| Form 8-K - Current report |
| 06/12/2012 |
GN
| PolyMedix Receives USAN Approval for Generic Name of Brilacidin for PMX-30063 |
| 06/04/2012 |
GN
| New Data on PMX-30063 Presented at ASCO Suggest Strong Potential as Treatment for Oral Mucositis |
| 05/10/2012 |
10-Q
| Quarterly Report for the period ended May 9, 2012 |
| 05/10/2012 |
GN
| PolyMedix Provides Update on PMX-60056 Program |
| 05/04/2012 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 04/23/2012 |
8-K
| Investor presentation |
| 04/23/2012 |
GN
| PolyMedix Announces Positive Results From Phase 2 Clinical Trial With PMX-30063 First-in-Class Defensin-Mimetic Antibiotic |
| 04/20/2012 |
GN
| PolyMedix to Review Full Results From Phase 2 Clinical Trial With PMX-30063 Defensin-Mimetic Antibiotic |
| 04/10/2012 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"Loan and Security Agreement by and among PolyMedix, Inc., PolyMedix Pharmaceuticals, Inc., MidCap Financial SBIC, LP, as administrative agent, and the lenders listed thereto from time to time",
"Warrant to Purchase Common Stock",
"Registration Rights Agreement by and between PolyMedix, Inc. and MidCap Financial SBIC, LP",
"PolyMedix Restructures its Debt and Secures $12 Million Credit Facility" |
|
| 04/10/2012 |
8-K
| Form 8-K - Current report |
| 04/10/2012 |
GN
| PolyMedix Restructures Its Debt and Secures $12 Million Credit Facility |
| 03/28/2012 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|